L3VLUP
ProSign in

MRK · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRKVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRK
  • VRTX
0204060202120222023202420252026
Holders and value by quarter
QuarterMRKVRTX
Q3 202035 holders, $20.2bn31 holders, $21.9bn
Q4 202034 holders, $19.1bn30 holders, $18.4bn
Q1 202133 holders, $16.6bn31 holders, $15.4bn
Q2 202131 holders, $15.1bn30 holders, $12.7bn
Q3 202131 holders, $15.2bn35 holders, $10.1bn
Q4 202126 holders, $15.0bn28 holders, $12.4bn
Q1 202234 holders, $17.4bn23 holders, $16.1bn
Q2 202234 holders, $19.0bn25 holders, $18.1bn
Q3 202235 holders, $17.2bn22 holders, $18.4bn
Q4 202235 holders, $25.2bn28 holders, $18.4bn
Q1 202333 holders, $26.6bn26 holders, $21.4bn
Q2 202334 holders, $30.1bn27 holders, $24.7bn
Q3 202339 holders, $26.7bn33 holders, $24.3bn
Q4 202341 holders, $29.3bn32 holders, $28.6bn
Q1 202437 holders, $37.1bn31 holders, $29.8bn
Q2 202438 holders, $33.0bn29 holders, $33.4bn
Q3 202438 holders, $29.1bn27 holders, $33.5bn
Q4 202435 holders, $23.7bn26 holders, $28.5bn
Q1 202536 holders, $20.8bn21 holders, $35.4bn
Q2 202531 holders, $18.5bn21 holders, $32.3bn
Q3 202536 holders, $19.0bn22 holders, $25.9bn
Q4 202532 holders, $26.8bn26 holders, $31.8bn
Q1 202630 holders, $28.9bn25 holders, $31.8bn
Q2 202625 holders, $29.2bn26 holders, $34.6bn
MRK

Merck & Co Inc

Holders
36
Reported value
$20.8bn
Buyers
20
Sellers
18

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
21
Reported value
$35.4bn
Buyers
10
Sellers
11

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2025

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MRK (22)

Acadian Asset Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Harris Associates LP, Holocene Advisors LP, Man Group PLC, Moore Capital Management LP, Quantbot Technologies LP, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Walleye Capital LLC

Only VRTX (7)

ARK Investment Management LLC, Baillie Gifford & Co, Capital World Investors, Element Capital Management LLC, Marshall Wace LLP, PDT Partners LLC, Renaissance Technologies LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →